<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AJAC</journal-id><journal-title-group><journal-title>American Journal of Analytical Chemistry</journal-title></journal-title-group><issn pub-type="epub">2156-8251</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ajac.2019.108024</article-id><article-id pub-id-type="publisher-id">AJAC-94581</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Substandard/Falsification Antibacterial Agents: A Systematic Review of Liquid Chromatographic and Spectrophotometric Methods for Their Detection
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pierrot</surname><given-names>Mwamba Tshilumba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moke</surname><given-names>Muindu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mutshitshi</surname><given-names>Kasongo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Gaelle</surname><given-names>Kalonji Mujinga</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mbedi</surname><given-names>Zabakani</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Joel</surname><given-names>Kabadi Kasongo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Musumba</surname><given-names>Tshamba</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean-Claude</surname><given-names>Nkwanga</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Roland</surname><given-names>Marini Djang’eing’a</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pierre</surname><given-names>Duez</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean-Baptiste</surname><given-names>Kalonji Ndoumba</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Laboratory of Analytical Chemistry, CIRM, Department of Pharmacy, Liege University, Liège, Belgium</addr-line></aff><aff id="aff2"><addr-line>Departement of Pharmacology and Toxicology, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo</addr-line></aff><aff id="aff1"><addr-line>Laboratory of Drug Analysis and Galenic, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo</addr-line></aff><aff id="aff4"><addr-line>Laboratory of Therapeutic Chemistry and Pharmacognosy, University of Mons, Mons, Belgium</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2019</year></pub-date><volume>10</volume><issue>08</issue><fpage>348</fpage><lpage>365</lpage><history><date date-type="received"><day>22,</day>	<month>July</month>	<year>2019</year></date><date date-type="rev-recd"><day>23,</day>	<month>August</month>	<year>2019</year>	</date><date date-type="accepted"><day>26,</day>	<month>August</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Falsified antibacterial agents continue to pose serious public health problems around the world. They are notably responsible for resistance emergence in the treatment of infectious diseases that can lead to death. The aim of this study was to summarize the literature on the methods developed and validated to detect poor quality antibacterial agents in order to assess the impact of these available methods in the fighting against Counterfeit/substandard medicines. Thus, studies published in the time from January 2000 to July 2017, were accessible via Google Scholar and Pubmed and allowed to analyze 41 papers. The majority (30) of developed and validated methods concerned LC methods, 9 regarded UV/V is spectrophotometry and two studies simultaneously developed both methods. Antibacterial agents belonging to beta-lactams group were the most concerned by the methods developed and validated (39%), followed by quinolones (18%) and macrolides (12%). Regarding active ingredients, amoxicillin (12%) was the most concerned by the development and validation methods. In spite of several available methods to detect substandard drugs, antibacterial agents for which methods were developed and validated were the most concerned by worldwide detected non-conformities. The fight against this scourge should not be only limited by their detection, but it also requires an effective involvement of different actors notably: health authorities, international organizations, pharmaceutical industries etc.
 
</p></abstract><kwd-group><kwd>Counterfeiting/Falsification/Substandard Antibacterial</kwd><kwd> Liquid Chromatography/Spectrophotometry UV/Vis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Counterfeit/substandard drugs are becoming an increasing source of risks for public health [<xref ref-type="bibr" rid="scirp.94581-ref1">1</xref>]. They are responsible for several cases of morbidity and mortality in the world [<xref ref-type="bibr" rid="scirp.94581-ref2">2</xref>]. These drugs notably increase the risks of treatment failure in various diseases but can also be at the origin of drug poisoning [<xref ref-type="bibr" rid="scirp.94581-ref3">3</xref>]. Moreover, suboptimal dosages of antibacterial agents undoubtedly contribute to the emergence of bacterial resistance [<xref ref-type="bibr" rid="scirp.94581-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref5">5</xref>].</p><p>Despite a series of studies on counterfeit/substandard medicines and efforts provided by the health authorities in various countries to fight them, the rate of dubious quality drugs continues to rise [<xref ref-type="bibr" rid="scirp.94581-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref7">7</xref>]. It is reported that more than 10.5% of drugs in circulation worldwide are of low quality (counterfeit, substandard) [<xref ref-type="bibr" rid="scirp.94581-ref8">8</xref>].</p><p>In addition, several studies indicate that because of the lack of pharmaceutical regulation and/or controls, the circulation of counterfeit/substandard drugs mainly affects developing countries, through an expanding illicit market [<xref ref-type="bibr" rid="scirp.94581-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref12">12</xref>]. In these countries, the falsification of antibacterial agent and other antiparasitic agents is particularly prevalent, with alarming and life-threatening consequences for the most prevalent diseases, such as malaria, tuberculosis and other opportunistic HIV infection-related diseases [<xref ref-type="bibr" rid="scirp.94581-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref13">13</xref>]. Moreover, a major cause of the increasing failures rate in the management of infectious diseases in low-income countries resides in the use of low-quality antibacterial agent. In this context, it is opportune to combat the circulation of counterfeit/substandard antibacterial agent [<xref ref-type="bibr" rid="scirp.94581-ref13">13</xref>]. This increasing rate in the management of infectious diseases due to counterfeit/substandard antibacterial agent, represents the main problem of public health. It is established that an effective fight against counterfeit and substandard drugs relies on their detection, notably through a careful visual inspection of the product, the packaging and the galenic form [<xref ref-type="bibr" rid="scirp.94581-ref11">11</xref>]. Other elements can be also checked, such as the accuracy of bar codes and holograms eventually indicated on the packaging. However, the increased sophistication of counterfeiters often allows them to correctly reproduce the packaging and appearance of galenic forms, so that the visual examination alone cannot differentiate the authentic from the counterfeit [<xref ref-type="bibr" rid="scirp.94581-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref14">14</xref>].</p><p>The investigation of drugs authenticity can be also conducted to detect falsified drugs. It consists essentially to contact the manufacturers and regulatory authorities of marketing and manufacturing countries; the manufacturer can formally attest drug authenticity which he has produced [<xref ref-type="bibr" rid="scirp.94581-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref13">13</xref>]. Indeed, Drug regulatory authorities can provide essential information on legality of products which are in circulation in the country. But, It is not obvious to obtain always reliable information from the manufacturer if himself decided to falsify his own product for beneficial reasons, this can be achieved either by reducing the cost of presentation of packaging or by using less expensive excipients than those used in the manufacturing of original product, either by producing the same drug in another country where labor is not at expensive or even reducing the exact dose of active ingredient that is eventually expensive. In addition, it is not always easy to achieve this investigation successfully because of the incertitude that exists to have a frank collaboration with the manufacturers and the health authorities of some countries.</p><p>The considerations mentioned above indicate that these methods are limited to ensure an optimal detection of falsified drugs. Thus, analytical methods offer an interesting alternative to detect counterfeit/substandard drugs. So, there are several analytical methods including: gas chromatography, high performance liquid chromatography (HPLC), mass spectroscopy, UV/VIS spectrophotometry, near infrared spectroscopy (NIR), capillary electrophoresis, thin layer chromatography, ... [<xref ref-type="bibr" rid="scirp.94581-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref16">16</xref>].</p><p>Several studies focused on development and validation methods analytical to determine the content of active ingredient. Some of them are complex and expensive; others are simples, inexpensive and rapids [<xref ref-type="bibr" rid="scirp.94581-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref18">18</xref>]. It has been reported that among the analytical methods used to analyze drugs, HPLC was the most commonly used method to control drugs quality [<xref ref-type="bibr" rid="scirp.94581-ref19">19</xref>]. Indeed, HPLC is a separation technique widely applied in quantitative and qualitative analysis [<xref ref-type="bibr" rid="scirp.94581-ref16">16</xref>]. Elsewhere, most of laboratories in low-income countries do not always have the capacity to get sophisticated equipment such as Liquid Chromatography, mass spectroscopy, capillary electrophorese, to applicate analytical methods. They use simple and less costly methods, among which UV/VIS spectrophotometry has an important role in the detection of poor quality medicines [<xref ref-type="bibr" rid="scirp.94581-ref17">17</xref>]. UV/VIS spectrophotometry is a non-separative technique which is related to the interaction of light with matter [<xref ref-type="bibr" rid="scirp.94581-ref15">15</xref>].</p><p>Some revues focused on the usual methods of detecting counterfeit/substandard drugs [<xref ref-type="bibr" rid="scirp.94581-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref16">16</xref>]. Kovacs et al. (2014) identified methods for detecting counterfeit/substandard drugs, they classified them according to their cost, the need of sample preparation, the need of reagents, etc. [<xref ref-type="bibr" rid="scirp.94581-ref20">20</xref>]. A systematic review was also conducted on analytical methods to detect counterfeit/substandard drugs; the study covered 2010-2016 [<xref ref-type="bibr" rid="scirp.94581-ref21">21</xref>]. The authors focused specifically on digital technologies that exist to ensure the integrity of the supply chain to combat fake medicines. The above studied didn’t sufficiently study a certain number of parameters such as: the active ingredient concerned by the validated and developed methods, the information on the diluent, mobile phase and the wavelength in which the methods were developed and validated. This present study takes into account those parameters. Thus, the aim of this study is to summarize the literature on the methods developed and validated to detect poor quality antibacterial agents in order to assess the impact of these available methods in the fight against counterfeit medicines.</p></sec><sec id="s2"><title>2. Method</title><p>The literature choice was made using online databases: Google Scholar and Pubmed. The combination of terms such as: “detection counterfeit/substandard drugs”, “method detection counterfeit drugs”. In order to be more specific, the combination of the following words was also performed: “spectrophotometric/LC/development/validation antibacterial agent”, method determination antibacterial agent substandard/counterfeit. The articles concerned by this study are those published in 2000 and July 2017. The review was performed in accordance with the PRISMA statement [<xref ref-type="bibr" rid="scirp.94581-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref22">22</xref>].</p><p>We considered only articles published in English and French. We took into account studies which concerned exclusively LC and UV/visible spectrophotometry methods developed and validated to determine the content of active ingredient in pharmaceutical formulations. In addition, drugs involved were those having antibacterial action.</p><p>Elsewhere, studies focused only on 1) quality control of drugs, 2) development and validation of methods of drugs not having an antibacterial effect, 3) active ingredient didn’t clearly mentioned for the developed method 3) methods developed and validated but whose determination of the content of active ingredient were carried out in biological fluids (serum, plasma, urine, blood, bronchial secretions) were not taken into account.</p><p>First, the examination of articles titles were done in order to judge the conformity of articles according to our inclusion criteria. Thus, some articles were excluded from the study because the title didn’t meet our inclusion criteria. About articles having titles that raise up doubts or were ambiguous, the analysis of abstracts were necessary to be applied. Full-text of all titles that appeared to fit the purpose of the present study were obtained and analyzed to determine if they met inclusion criteria defined of the study.</p><p>The articles selected were evaluated in accordance to 14 parameters that were established in this study, these parameters were taken from each selected article: the active ingredient concerned, the type of method concerned, the apparatus(s) used, the mobile phase used, the diluent(s) used, the wavelength, the linearity, the specificity, the precision, the accuracy, the robustness, the correlation coefficient, the limit of detection and quantification. The data entry was done on the Microsoft Excel (version 2013) and data analyze were performed on Epi-info software (version7.0).</p></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. General Aspect</title><p>We identified 853 (<xref ref-type="fig" rid="fig1">Figure 1</xref>) articles in the database selected. 742 articles were excluded from the study for several reasons 1) they were not published between 2000 and July 2017; 2) it concerned systematic reviews article; 3) only quality</p><p>control of drugs were concerned; 4) they treated others methods than UV/vis spectrophotometric and LC; 5) the active ingredient concerned in the study had not an antibacterial action; 6) they treated other subjects which did not correspond to the aim of our objective of study. Thus, we retained first a total of 111 items.</p><p>Of these 111 items, 27 were excluded mainly because UV/vis spectrophotometric and HPLC methods developed for the antibacterial agents were performed in biological fluids (serum, bronchial secretions, plasma, and urine). It is important to note that 4 additional studies were included after references screening.</p><p>All 88 articles did not meet 14 evaluation criteria established, 27 met 13 criteria, 11 met 12, and respectively five, three and one studies met nine, 11 and 10 criteria. A total of 41 studies met therefore all 14 criteria established in the study.</p><p>Of these 41 studies, five studies were published in 2014, five in 2012, five in 2011, four in 2015, three studies were published in 2008 and in 2013, while other years did not exceed two publications. Any publication was not identified during 2000, 2001, 2005 and 2010.</p></sec><sec id="s3_2"><title>3.2. Characteristics of Methods and Active Ingredients</title><p>As described above, LC is considered as the gold standard analytical in drug analysis. 30 studies used LC to develop and validate methods in order to determine the content of active ingredient of antibacterial agents. However, nine studies used UV/vis spectrophotometry and two studies simultaneously developed both methods. Studies based on HPLC used an average wavelength of 260.8 nm &#177; 40.92. The range was of 205 to 360 nm. On the other hand, in UV/vis spectrophotometry, the average wavelength was 418.3 &#177; 101.72 and the range was of 210 to 540 nm.</p><p>In 7 studies [<xref ref-type="bibr" rid="scirp.94581-ref23">23</xref>] - [<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>] , UV/vis spectrophotometry methods developed of active ingredients consisted on the formation of a colored compound, which shown a maximum absorption, measurable on a spectrophotometer at a specific wavelength, whereas 4 studies [<xref ref-type="bibr" rid="scirp.94581-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref33">33</xref>] did not proceed on the formation of a colored compound. Elsewhere, studies carried out on HPLC were based on reversed phase chromatography coupled to UV detector.</p><p>33 antibacterial agents (<xref ref-type="table" rid="table1">Table 1</xref>) were concerned in the development and validation methods. Beta-lactams were widely represented with 13 antibacterial agents (39%), quinolones were concerned with six active ingredients (18%), and they were followed by macrolides (12%) for four antibacterial agents, three for cyclins (9%) and two actives substances belonging to lincosamides (6%) and two others to nitro-imidazoles (6%) Others groups: aminoglycoside, beta-lactamase inhibitor and antituberculous drugs provided only one active ingredient.</p><p>Development and validation of methods to determine the content of amoxicillin were carried out in five studies (12%), three were determined by LC method and two by UV/vis spectrophotometry method. The detection system of amoxicillin was performed at 215, 254 and 283 nm by LC [<xref ref-type="bibr" rid="scirp.94581-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref36">36</xref>]. In UV/vis spectrophotometry the content of amoxicillin were achieved at 397 nm and the method was based on the selective oxidation of amoxicillin with cerium (IV) or iron to give an intense yellow coloring product [<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>]. Another study developed UV/vis spectrophotometry method by using 4 different wavelengths: 390 nm, 520 nm, 435 nm, and 415 nm (Salem, 2004). The study used 4 procedures: 1) nitration and subsequent complexation with a nucleophilic reagent; 2) nitrosation and subsequent metal chelation; 3) coupling with diazo reagent; and 4) reaction with copper and extraction of the resulting chelate into chloroform [<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>].</p><p>Doxicyclin were studied in 4 studies (10%), all of them were developed by using LC methods at 360 nm, 277 nm, 310 nm and 410 nm, respectively [<xref ref-type="bibr" rid="scirp.94581-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref38">38</xref>]</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of methods based on HPLC and UV spectrophotometry</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >Antibacterial agent</th><th align="center" valign="middle" >Number of times used</th><th align="center" valign="middle" >Method type</th><th align="center" valign="middle" >Diluent</th><th align="center" valign="middle" >Mobile phase</th><th align="center" valign="middle" >Detection system (nm)</th><th align="center" valign="middle" >Reference</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >Clavulanic acid</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" >methanol:KH2PO4 (95:5)</td><td align="center" valign="middle" >215, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref35">35</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Acetonitrile:water (1:1)</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (70:30)</td><td align="center" valign="middle" >228</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref50">50</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >Amoxicilin</td><td align="center" valign="middle"  rowspan="5"  >5</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" >methanol:KH2PO4 (95:5)</td><td align="center" valign="middle" >215, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref35">35</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >methanol:water (2:98)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >397, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >KHPO4</td><td align="center" valign="middle" >Methanol:KHPO4:(5:95)</td><td align="center" valign="middle" >254</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref36">36</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >HNO3:HSO4:water (2:2:96)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >390, 520, 435, 415</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >KH2PO4 et methanol (95:5)</td><td align="center" valign="middle" >methanol:KH2PO4 (5:95)</td><td align="center" valign="middle" >283</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref34">34</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Azythromycin</td><td align="center" valign="middle"  rowspan="3"  >3</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >m&#233;thanol:H3PO4 (80:20)</td><td align="center" valign="middle" >210, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref46">46</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >540, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref27">27</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:water (40:60)</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (50:50)</td><td align="center" valign="middle" >215, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref47">47</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Cefadroxyl</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >methanol:water (2:98)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >397, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >HNO3:HSO4:water (2:2:96)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >390, 520, 435, 415</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>]</td></tr><tr><td align="center" valign="middle" >Cefdinir</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >210, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref25">25</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Cefoperazone</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" >KHPO4:acetonitrile (80:20)</td><td align="center" valign="middle" >230, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref43">43</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >HNO3:HSO4:water (2:2:96)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >390, 520, 435, 415</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>]</td></tr><tr><td align="center" valign="middle" >Cefozopran</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" >Ammonium acetate:acetonitrile (92:8)</td><td align="center" valign="middle" >260</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref54">54</xref>]</td></tr><tr><td align="center" valign="middle" >Cefpirome</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" >Ammonium acetate:acetonitrile (90:10)</td><td align="center" valign="middle" >270</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref55">55</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Cefpodoxime</td><td align="center" valign="middle"  rowspan="3"  >3</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:water (1:1)</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (70:30)</td><td align="center" valign="middle" >228</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref50">50</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:methanol:water (20:50:30)</td><td align="center" valign="middle" >acetonitrile:methanol:acetate trifluore (30:50:20)</td><td align="center" valign="middle" >235</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref45">45</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (70:30)</td><td align="center" valign="middle" >248</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref56">56</xref>]</td></tr><tr><td align="center" valign="middle" >Cefprozyl</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >methanol:water (2:98)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >397, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>]</td></tr><tr><td align="center" valign="middle" >Ceftiofur</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >292, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref31">31</xref>]</td></tr><tr><td align="center" valign="middle" >Ceftrizoxime</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >methanol:water (20:80)</td><td align="center" valign="middle" >methanol:water (20:80)</td><td align="center" valign="middle" >290, 0</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref57">57</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Claritromicin</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >Mobile phase A: methanol:KH2PO4:triethylamine (30:69.7:0.3); mobile phase B: acetonitrile</td><td align="center" valign="middle" >277</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref37">37</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >Mobile phase A:KH2PO4:octanesulfonic acid (5:1) phase B: acetonitrile (Phase B)</td><td align="center" valign="middle" >210</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>]</td></tr><tr><td align="center" valign="middle" >Clindamycine</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:HCl 0.1 N (50:50)</td><td align="center" valign="middle" >Phase A: buffer carbonate:acetonitrile (90:10) Phase B: buffer carbonate:acetonitrile (20:80)</td><td align="center" valign="middle" >214</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref58">58</xref>]</td></tr><tr><td align="center" valign="middle" >Demeclocycline</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >HCl 0.01 M</td><td align="center" valign="middle" >Phase A: acetonitrile:sodiul edelate:phosphate tetrapropylammonium hydrogene:water (2:35:35:28) Phase B: (30:35:35:0)</td><td align="center" valign="middle" >280</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref48">48</xref>]</td></tr><tr><td align="center" valign="middle" >Dicloxacillin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:methanol:water (20:50:30)</td><td align="center" valign="middle" >acetonitrile:methanol:acetate trifluore (30:50:20)</td><td align="center" valign="middle" >235</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref45">45</xref>]</td></tr><tr><td align="center" valign="middle" >Doxicyclin</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >HCl 0.001 M</td><td align="center" valign="middle" >water-acetonitrile (60:40)</td><td align="center" valign="middle" >360</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref40">40</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  ></th><th align="center" valign="middle"  rowspan="3"  ></th><th align="center" valign="middle" >HPLC</th><th align="center" valign="middle" >Methanol</th><th align="center" valign="middle" >Mobile phase A: methanol:KH2PO4:triethylamine (30:69.7:0.3); mobile phase B: acetonitrile</th><th align="center" valign="middle" >277</th><th align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref37">37</xref>]</th></tr></thead><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >Mobile phase A: KH2PO4:octanesulfonic acide (5:1) phase B: acetonitrile (Phase B)</td><td align="center" valign="middle" >310</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >KH2PO4:methanol (2:8)</td><td align="center" valign="middle" >KH2PO4:methanol (3:7)</td><td align="center" valign="middle" >400</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref38">38</xref>]</td></tr><tr><td align="center" valign="middle" >Enrofloxacin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >KH2PO4:Acetonitrile (75:25)</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (75:25)</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref59">59</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Gatifloxacin</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Buffer citrate:acetonitrile (52:48)</td><td align="center" valign="middle" >buffer citrate:acetonitrile (52:48)</td><td align="center" valign="middle" >292</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref53">53</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >412, 415, 417, 414</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref23">23</xref>]</td></tr><tr><td align="center" valign="middle" >Gemifloxacin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >270</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref30">30</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Imipenem</td><td align="center" valign="middle"  rowspan="2"  >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >methanol:water (50:50)</td><td align="center" valign="middle" >methanol:orthophosphoric acid (60:40)</td><td align="center" valign="middle" >225</td><td align="center" valign="middle"  rowspan="2"  >[<xref ref-type="bibr" rid="scirp.94581-ref26">26</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >525</td></tr><tr><td align="center" valign="middle" >Josamycin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:water (3:7)</td><td align="center" valign="middle" >acetonitrile:buffer phosphate:hydrogeno sulfate tetrabutylammonium:water (21:5:3:71)</td><td align="center" valign="middle" >232</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref44">44</xref>]</td></tr><tr><td align="center" valign="middle" >Levofloxacin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:water (1:1)</td><td align="center" valign="middle" >water:acetonitrile (6:5)</td><td align="center" valign="middle" >260, 265, 270, 275, 280</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref60">60</xref>]</td></tr><tr><td align="center" valign="middle" >Lincomycin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Ethanol</td><td align="center" valign="middle" >acetonitrile:buffer phosphate (89:11)</td><td align="center" valign="middle" >220</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref61">61</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Meropenem</td><td align="center" valign="middle"  rowspan="2"  >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" >KH2PO4:acetonitrile (9:1)</td><td align="center" valign="middle" >298,0</td><td align="center" valign="middle"  rowspan="2"  >[<xref ref-type="bibr" rid="scirp.94581-ref32">32</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >298,0</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Metronidazole</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >KHPO4</td><td align="center" valign="middle" >KHPO4:methanol (95:5)</td><td align="center" valign="middle" >254</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref36">36</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:methanol (80:20)</td><td align="center" valign="middle" >NaHPO4:acetonitrile (65:35)</td><td align="center" valign="middle" >319</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref51">51</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="4"  >Moxifloxacin</td><td align="center" valign="middle"  rowspan="4"  >4</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >methanol:KH2PO4 (62:38)</td><td align="center" valign="middle" >254</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref42">42</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >Water</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >623, 660</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref24">24</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acide phosphorique 0.1%</td><td align="center" valign="middle" >water (triethlyamine2%):acetonitrile (90:10)</td><td align="center" valign="middle" >290</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref41">41</xref>]</td></tr><tr><td align="center" valign="middle" >Spectro</td><td align="center" valign="middle" >1) HCl 0.1 N 2) tampon phosphate</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >296, 289</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref33">33</xref>]</td></tr><tr><td align="center" valign="middle" >Norfloxacine</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >Mobile phase A: KH2PO4:octanesulfonic acid (5:1) phase B: acetonitrile (Phase B)</td><td align="center" valign="middle" >310</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>]</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Oxytetracyclin</td><td align="center" valign="middle"  rowspan="2"  >2</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >HCl 0.01 M</td><td align="center" valign="middle" >Phase A: 0.05% trifluoroacetic acid in water; phase B: acetonitrile:methanol:tetrahydrofuran (80:15:5)</td><td align="center" valign="middle" >254</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref49">49</xref>]</td></tr><tr><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >methanol:acetonitrile:buffer phosphate (12.5:12.5:75)</td><td align="center" valign="middle" >253</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref52">52</xref>]</td></tr><tr><td align="center" valign="middle" >Rifampicine</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (50:50)</td><td align="center" valign="middle" >acetonitrile:KH2PO4 (50:50)</td><td align="center" valign="middle" >238</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref62">62</xref>]</td></tr><tr><td align="center" valign="middle" >Roxithromycin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Ethanol</td><td align="center" valign="middle" >KH2PO4:acetonitrile (50:50)</td><td align="center" valign="middle" >205</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref63">63</xref>]</td></tr><tr><td align="center" valign="middle" >Spectinomycin</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >acetonitrile:tampon phosphate (89:11)</td><td align="center" valign="middle" >acetonitrile:buffer phosphate (89:11)</td><td align="center" valign="middle" >220</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref61">61</xref>]</td></tr><tr><td align="center" valign="middle" >Tinidazole</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >HPLC</td><td align="center" valign="middle" >Methanol</td><td align="center" valign="middle" >Mobile phase A: KH2PO4:acide octanesulfonic acid (5:1) phase B: acetonitrile (Phase B)</td><td align="center" valign="middle" >310</td><td align="center" valign="middle" >[<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>]</td></tr></tbody></table></table-wrap></table-wrap-group><p>[<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref40">40</xref>]. On the other hand, UV/vis spectrophotometry method permitted to develop and validate methods to quantify the amount of moxifloxacin [<xref ref-type="bibr" rid="scirp.94581-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref33">33</xref>]. In addition, LC method were also used to determine the content of moxifloxacin, the wavelength were performed at 254 nm and 290 nm [<xref ref-type="bibr" rid="scirp.94581-ref41">41</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref42">42</xref>]. One of the method used to develop the LC method of moxifloxacin consists to separate and determine impurities and degradation products of moxifloxacin in its pharmaceutical forms [<xref ref-type="bibr" rid="scirp.94581-ref41">41</xref>].</p><p>The methods developed of cefpodoxime were all based on LC method [<xref ref-type="bibr" rid="scirp.94581-ref43">43</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref45">45</xref>]. Azithromycin has been also studied in 3 studies (7%). HPLC method were useful for 2 of them whereas 1 used UV spectrophotometry which were based on the reaction of azithromycin with p-chloranil in order to obtain a compound colored in red and measurable at the spectrophotometer at 540 nm [<xref ref-type="bibr" rid="scirp.94581-ref27">27</xref>]. The detection system of azythromycin used in HPLC was performed at 210 nm and 215 nm [<xref ref-type="bibr" rid="scirp.94581-ref46">46</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref47">47</xref>].</p><p>Potassium clavulanate, clarithromycin, metronidazole and oxytetracyclin were all performed by HPLC [<xref ref-type="bibr" rid="scirp.94581-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref48">48</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref49">49</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref50">50</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref51">51</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref52">52</xref>]. Two wavelengths (215 and 228 nm) permitted to detect potassium clavulanate. The detection system was performed at 319 nm for metronidazole, 253 nm for oxytetracyclin, 210 and 277 nm for clarithromycin.</p><p>Cefadroxyl were concerned in two studies (5%), all of them used UV/vis spectrophotometry method. Indeed, one study used four different wavelengths: 390 nm, 520 nm, 435 nm, and 415 nm as mentioned above with the case of amoxicillin [<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>]. In another study, the wavelength were performed at 397 nm and the method was based on the selective oxidation of these drugs with either Ce (IV) or Fe (III) in acid medium to give an intense yellow colored product [<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>].</p><p>Gatifloxacin were concerned in 2 studies (5%), which one used UV/vis spectrophotometry method based on the formation of yellow ion pair complexes between the basic nitrogen of the drug and three sulfonphthalein acid dyes and the wavelength were performed at 412 nm, 415 nm, 417 nm and 414 nm [<xref ref-type="bibr" rid="scirp.94581-ref23">23</xref>]. The wavelength performed in HPLC for gatifloxacin was at 292 nm [<xref ref-type="bibr" rid="scirp.94581-ref53">53</xref>]. Cefoperazone were also concerned in 2 studies, one used UV/vis spectrophotometry method as it described above about Cefadroxyl [<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>]. The system detection in HPLC method of cefoperazone was at 292 nm [<xref ref-type="bibr" rid="scirp.94581-ref43">43</xref>].</p><p>Others antibacterial agents (cefozopran, cefpirome, ceftrizoxime, clindamycin, demeclocycline, dicloxacillin, enrofloxacin, imipenem, levofloxacin, lincomycin, meropenem, norfloxacin, rifampicin, roxithromycin, spectinomycin and tinidazole) were concerned in one study by using HPLC method as shown in <xref ref-type="table" rid="table1">Table 1</xref>. On the other hand, cefdinir, cefprozyl, ceftiofur and gemifloxacin were concerned also in one study, but UV/vis spectrophotometry method was used. It fit to note that two different studies used the same wavelength in the development and validation of a method of metronidazole and oxytetracyclin by LC. It fit to note that, three studies used the same wavelength (254 nm) to describe the LC method of amoxicillin, metronidazole, moxifloxacin and oxytetracyclin. The LC method of amoxicillin and azythromycin has also been performed at the same wavelength (215 nm) in two different studies [<xref ref-type="bibr" rid="scirp.94581-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref49">49</xref>].</p></sec><sec id="s3_3"><title>3.3. Diluents, Mobile Phase and Others Validation Parameters</title><p>The use of diluents is essential, whatever UV/vis spectrophotometry or LC method. The water were the preferred diluent (9 studies) for preparing antibacterial agents [<xref ref-type="bibr" rid="scirp.94581-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref54">54</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref55">55</xref>]. Indeed, of these 9 studies, water was used as diluent in 4 studies which concerned LC methods. Four others concerned UV/vis spectrophotometry methods. In one study water were used as diluent to develop LC and UV spectrophotometry method [<xref ref-type="bibr" rid="scirp.94581-ref32">32</xref>].</p><p>Methanol was used in 8 studies: 5 for LC and 3 for UV/vis spectrophotometry method [<xref ref-type="bibr" rid="scirp.94581-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref46">46</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref52">52</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref56">56</xref>] whereas the mixture acetonitrile:water was used in 4 studies. The mixture acetonitrile:phosphate buffer in 3 studies [<xref ref-type="bibr" rid="scirp.94581-ref59">59</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref61">61</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref62">62</xref>].</p><p>The proportion of solvent mixture was different in studies mentioned above, except for two studies, where the same mixture solvent and proportion were used [<xref ref-type="bibr" rid="scirp.94581-ref50">50</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref60">60</xref>]. Moreover, the diluent mixtures were often used for LC methods except two studies which used a solvent mixture (methanol:water) to develop a UV/vis spectrophotometry method [<xref ref-type="bibr" rid="scirp.94581-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref29">29</xref>]. Other diluents were used in one or two studies as detailed in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>Regarding the mobile phase, mixture acetonitrile:buffer were used in 10 studies for the development and validation methods whereas the mixture methanol:buffer were used in 5 studies as mentioned in <xref ref-type="table" rid="table1">Table 1</xref>. It fit to note that 1) two studies used the same mobile phase (acetonitrile:buffer phosphate) at the same proportion (70:30) for the same antibacterial agent (cefpodoxime), except the wavelength (248 nm and 228 nm) and the diluent (methanol and acetonitrile:water) [<xref ref-type="bibr" rid="scirp.94581-ref50">50</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref56">56</xref>].</p><p>The parameters validation: specificity/selectivity, precision, accuracy, robustness, linearity, correlation coefficient and limit of detection and quantification, were determined in all 41 studies concerned.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>Poor quality antibacterial agents are real threats for the public health, mainly because of the phenomena of resistance that they can cause [<xref ref-type="bibr" rid="scirp.94581-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref5">5</xref>]. Several cases of resistance has been reported notably, the case of the management of urinary tract infections which were successfully treated with colistin. Indeed, the emergence of the mechanism resistance of colistin via an MCR-plasmid was reported [<xref ref-type="bibr" rid="scirp.94581-ref64">64</xref>]. However, the fight against poor quality antibacterial agents can contribute to prevent the emergence of antimicrobial resistance [<xref ref-type="bibr" rid="scirp.94581-ref5">5</xref>]. In other words, an effective fighting against poor quality antibacterial agents, is to detect them. This shows that, the methods to detect falsified antibacterial agents are therefore a way which can guarantee also a better management of infectious diseases. This fighting requires the application of prior factors that are mainly less or not applied in many developing countries: 1) registration and authorization of drugs by the health authorities before their marketing; 2) promoting the use of WHO prequalified drugs [<xref ref-type="bibr" rid="scirp.94581-ref9">9</xref>].</p><p>Elsewhere, the purpose of this review were to summarize LC and UV/visible spectrophotometry methods developed and validated to detect antibacterial agent drugs of poor quality in terms of active ingredients. It should be noted that, the quality of a drug don’t always depend on a correct amount of active ingredient, other methods can be also taken into account such as dissolution test and disintegration test which can have an effect on therapeutic response.</p><p>In this study, several studies (31) used LC to develop and validate methods. The choice of LC methods may be justified by the fact that the results provided by the LC are generally reliable because of the high accuracy, sensitivity and selectivity obtained by this method comparing to UV/vis spectrophotometry. But we can note some of its disadvantages notably the high cost as reported by Kovacs et al. (2014), LC device costs about $50.000 and its use requires a highly qualified technician, it requires electricity at all times but also the consumption of reagents should be taken into account [<xref ref-type="bibr" rid="scirp.94581-ref20">20</xref>].</p><p>Antibacterial agents for which methods were developed and validated belonged to beta-lactam group (39%), followed by quinolones (18%), lincosamides (18%), macrolides (18%) and cyclins (9%). Besides, amoxicillin were the most concerned by the development and validation of methods. Also, it was the most falsified antibacterial agent for which non-conformities were reported in 29 countries [<xref ref-type="bibr" rid="scirp.94581-ref13">13</xref>]. Moreover, Delepierre et al. (2012) indicated that antibacterial agents belonging to beta-lactam group were the most counterfeited in the world (50%), followed by quinolones 12%, 11% for macrolides and lincosamides and 9% for cyclins [<xref ref-type="bibr" rid="scirp.94581-ref4">4</xref>]. These observations, show that there is a correlation between antibacterial agents for which methods are developed and substandard antibacterial agents detect in the world. However, the availability of these methods does not allow the eradication of falsified medicines. In other words, the fight against this scourge should not be only limited by their detection, but it also requires effective involvement of different actors notably: health authorities, policies, international organizations, pharmaceutical industries, and pharmacists...</p><p>It has been noted that, LC method used the lower wavelength values compared to those used in UV/vis spectrophotometry: The minimum wavelength value to develop LC methods were 205 nm and 360 nm for the maximum value whereas in UV spectrophotometry the minimum value was 210 nm and 540 nm for the maximum value. This can be explained by the fact that the UV detector used in LC is more sensitive and permit a rapid detection which doesn’t require great wavelength values. In their study, Kogawa et al. (2012), listed LC methods developed to quantify doxycycline in biologicals liquids [<xref ref-type="bibr" rid="scirp.94581-ref40">40</xref>]. This list indicated that the minimum wavelength value were 230 nm and 363 nm for the maximum value. It is clear that there is no significant difference between the values obtained in this study even if they studied on one molecule whereas several antibacterial agents were concerned in this study [<xref ref-type="bibr" rid="scirp.94581-ref40">40</xref>].</p><p>Knowledge of solubility is important in the pharmaceutical field. It allows scientists to choose the best diluent which can dissolve an active ingredient or a combination of two or three active ingredients in a sample [<xref ref-type="bibr" rid="scirp.94581-ref65">65</xref>]. This choice depends on the physic-chemical characteristics of the molecules under study. We reported in this study that water was the most used diluent, followed by methanol. This, confirm that water is not only the main diluent but also the most used in the pharmaceutical field [<xref ref-type="bibr" rid="scirp.94581-ref65">65</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref66">66</xref>]. In addition, the use of water has many advantages notably: ease to use, not dangerous for the manipulator and the environment and improvement of reactivity and selectivity. It is also less expensive compared to several other diluents [<xref ref-type="bibr" rid="scirp.94581-ref65">65</xref>] [<xref ref-type="bibr" rid="scirp.94581-ref66">66</xref>]. This is interesting for developing countries where acquisition solvent is a great problem to analyze drugs in laboratories. However, medications are often slightly soluble in water and their solubility should be increased. The study conducted by Jouyban (2008) indicated the methods used to improve the aqueous solubility of drugs, among these methods there is co-solvability, hydrotropism, complexation, ionization and the use of surfactants [<xref ref-type="bibr" rid="scirp.94581-ref67">67</xref>]. In this study, the active ingredients diluted in water were clavulanic acid, amoxicillin, cefoperazone, cefozopran and cefpirome for HPLC and ceftiofur, gatifloxacin, imipenem and moxifloxacin for UV/vis spectrophotometry. For meropenem, Mendez et al. (2003) used water as a diluent to develop both methods [<xref ref-type="bibr" rid="scirp.94581-ref32">32</xref>].</p><p>By analyzing antibacterial agents for which water has been used as diluent, 6 of them belonged to beta-lactam group and 2 to quinolones. The beta-lactams are constituted of penicillins and cephalosporins are weak acids characterized by high polarity and form the soluble salts in water [<xref ref-type="bibr" rid="scirp.94581-ref68">68</xref>]. On the other hand, quinolones are also weak acids but their aqueous solubility is low [<xref ref-type="bibr" rid="scirp.94581-ref69">69</xref>].</p><p>The choice of mobile phase depends primarily on the nature of the compounds to be separated. The mixture acetonitrile:phosphate buffer were the most used (11 studies) for methods development, followed by methanol: buffer (5 studies). The predominance of the use of acetonitrile can be justified by its physical properties which are exceptionally well adapted in LC. In addition mobile phases which containing other solvents often provide chromatograms wide and asymmetry peaks [<xref ref-type="bibr" rid="scirp.94581-ref70">70</xref>]. Yet, acetonitrile has some disadvantages including its toxicity and its high cost compared to other solvents such as acetone and methanol.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The aim of this study was to summarize liquid chromatography and UV/vis spectrophotometry methods developed and validated to detect antibacterial agents of poor quality in terms of active ingredient content in order to assess the impact of these available methods in the fighting against counterfeit/substandard medicines. It has been reported in this study that the antibacterial agents for which methods were developed and validated were the most concerned by worldwide detected non-conformities. Indeed, antibacterial agents for which methods were developed and validated belonged to beta-lactam group (39%), followed by quinolones (18%). In addition, amoxicillin (12%) was the active ingredient of the most concerned by the development and validation methods. This present study showed that it is obvious that the fight against substandard and falsification agent antibacterial should not be only limited by their detection, but it also requires an effective involvement of different actors notably: health authorities, international organizations, pharmaceutical industries etc. Moreover, the tracking of poor quality drugs cannot be therefore interrupted as far as the counterfeiters do not admit to being defeated. Despite the development of several methods to detect falsified drugs, counterfeiters continue to develop strategies to escape to the detection of falsified drugs that they are producing. Thus, there is a need to diversify and update methods detection. In addition, considering that falsified drugs are mainly consumed in poor countries, it is desirable to propose methods which are financially and technically feasible and require a minimum of infrastructure.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We thank the ARES-CCD (Academy of Research and Higher Education-Commission for Development Cooperation) for the support that that we received to carry out this study.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Tshilumba, P.M., Muindu, M., Kasongo, M., Mujinga, G.K., Zabakani, M., Kasongo, J.K., Tshamba, M., Nkwanga, J.-C., Djang’eing’a, R.M., Duez, P. and Ndoumba, J.-B.K. (2019) Substandard/Falsification Antibacterial Agents: A Systematic Review of Liquid Chromatographic and Spectrophotometric Methods for Their Detection. American Journal of Analytical Chemistry, 10, 348-365. https://doi.org/10.4236/ajac.2019.108024</p></sec></body><back><ref-list><title>References</title><ref id="scirp.94581-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Khuluza, F., Kigera, S. and Heide, L. (2017) Low Prevalence of Substandard and Falsified Antimalarial and Antibacterial Agent Medicines in Public and Faith-Based Health Facilities of Southern Malawi. The American Journal of Tropical Medicine and Hygiene, 96, 1124-1135. https://doi.org/10.4269/ajtmh.16-1008</mixed-citation></ref><ref id="scirp.94581-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Trippe, Z.A., Brendani, B., Meier, C. and Lewis, D. (2017) Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports. Drug Safety, 40, 293-303. https://doi.org/10.1007/s40264-016-0499-5</mixed-citation></ref><ref id="scirp.94581-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Peyraud, N., Rafael, F., Parker, L.A., Quere, M., Alcoba, G., Korff, C., et al. (2017) An Epidemic of Dystonic Reactions in Central Africa. The Lancet Global Health, 5, e137-e138. https://doi.org/10.1016/S2214-109X(16)30287-X</mixed-citation></ref><ref id="scirp.94581-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Delepierre, A., Gayot, A. and Carpentier, A. (2012) Update on Counterfeit Antibacterial Agents Worldwide; Public Health Risks. M&amp;eacute;decine et Maladies Infectieuses, 42, 247-255. https://doi.org/10.1016/j.medmal.2012.04.007</mixed-citation></ref><ref id="scirp.94581-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nwokike, J., Clark, A. and Nguyen, P.P. (2018) Medicines Quality Assurance to Fight Antimicrobial Resistance. Bulletin of the World Health Organization, 96, 135-137. https://doi.org/10.2471/BLT.17.199562</mixed-citation></ref><ref id="scirp.94581-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Almuzaini, T., Choonara, I. and Sammons, H. (2013) Substandard and Counterfeit Medicines: A Systematic Review of the Literature. British Medical Journal Open, 3, e002923. https://doi.org/10.1136/bmjopen-2013-002923</mixed-citation></ref><ref id="scirp.94581-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tshilumba, P.M., Amuri, S.B., Kaghowa, E.R., Mbikay, D.M., Impele, A.B., Duez, P., et al. (2015) Survey of Counterfeit Oral Antiinfectives Medecine Sold in Lubumbashi. The Pan African Medical Journal, 22, 318. https://doi.org/10.11604/pamj.2015.22.318.7302</mixed-citation></ref><ref id="scirp.94581-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2017) WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. World Health Organization, Geneva, Switzerland. http://www.who.int/medicines/regulation/ssffc/publications/GSMS_Report.pdf</mixed-citation></ref><ref id="scirp.94581-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">El-Jardali, F., Akl, E.A., Fadlallah, R., Oliver, S., Saleh, N., El-Bawab, L., et al. (2015) Interventions to Combat or Prevent Drug Counterfeiting: A Systematic Review. British Medical Journal Open, 5, e006290. https://doi.org/10.1136/bmjopen-2014-006290</mixed-citation></ref><ref id="scirp.94581-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ozawa, S., Evans, D.R., Bessias, S., Haynie, D.G., Yemeke, T.T., Laing, S.K., et al. (2018) Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries. JAMA Network Open, 1, e181662. https://doi.org/10.1001/jamanetworkopen.2018.1662</mixed-citation></ref><ref id="scirp.94581-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">D&amp;eacute;gardin, K., Roggo, Y. and Margot, P. (2014) Understanding and Fighting the Medicine Counterfeit Market. Journal of Pharmaceutical and Biomedical Analysis, 87, 167-175. https://doi.org/10.1016/j.jpba.2013.01.009</mixed-citation></ref><ref id="scirp.94581-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Tshilumba, P., Kagoha, E. and Chiribagula, V. (2016) Preliminary Study on Counterfeiting of Artemether and Artesunate Marketed in Lubumbashi. Pharmacology &amp; Pharmacy, 7, 185-192. https://doi.org/10.4236/pp.2016.75024</mixed-citation></ref><ref id="scirp.94581-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kelesidis, T. and Falagas, M.E. (2015) Substandard/Counterfeit Antimicrobial Drugs. Clinical Microbiology Reviews, 28, 443-464. https://doi.org/10.1128/CMR.00072-14</mixed-citation></ref><ref id="scirp.94581-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Oral, V. and Anda, S.&amp;Ccedil;. (2015) A Literature Review of Analytical Methods Used for Identification and Determination of Counterfeit Drugs. Journal of Pharmacy of Istanbul University, 45, 253-266.</mixed-citation></ref><ref id="scirp.94581-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Marini, R.D.G.E., Kindenge, J.M., De Mar&amp;iacute;a Lourdes Montes, A.J.A., Debrus, B., Lebrun, P., Mantanus, J., et al. (2010) Analytical Tools to Fight against Counterfeit Medicines. Chimica Oggi, 28, 10-14.</mixed-citation></ref><ref id="scirp.94581-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Martino, R., Malet-Martino, M., Gilard, V. and Balayssac, S. (2010) Counterfeit Drugs: Analytical Techniques for Their Identification. Analytical and Bioanalytical Chemistry, 398, 77-92. https://doi.org/10.1007/s00216-010-3748-y</mixed-citation></ref><ref id="scirp.94581-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kindenge Mbinze, J., Mpasi, J.N., Maghe, E., Kobo, S., Mwanda, R., Mulumba, G., et al. (2015) Application of Total Error Strategy in Validation of Affordable and Accessible UV-Visible Spectrophotometric Methods for Quality Control of Poor Medicines. American Journal of Analytical Chemistry, 6, 106-117. https://doi.org/10.4236/ajac.2015.62010</mixed-citation></ref><ref id="scirp.94581-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Habyalimana, V., Mbinze, J.K., Yemoa, A.L., Waffo, C., Diallo, T., Tshilombo, N.K., et al. (2017) Application of Design Space Optimization Strategy to the Development of LC Methods for Simultaneous Analysis of 18 Antiretroviral Medicines and 4 Major Excipients Used in Various Pharmaceutical Formulations. Journal of Pharmaceutical and Biomedical Analysis, 139, 8-21. https://doi.org/10.1016/j.jpba.2017.02.040</mixed-citation></ref><ref id="scirp.94581-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Koczwara, A. and Dressman, J. (2017) Poor-Quality and Counterfeit Drugs: A Systematic Assessment of Prevalence and Risks Based on Data Published From 2007 to 2016. Journal of Pharmaceutical Sciences, 106, 2921-2929. https://doi.org/10.1016/j.xphs.2017.05.018</mixed-citation></ref><ref id="scirp.94581-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kovacs, S., Hawes, S.E., Maley, S.N., Mosites, E., Wong, L. and Stergachis, A. (2014) Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries. PLoS ONE, 9, e90601. https://doi.org/10.1371/journal.pone.0090601</mixed-citation></ref><ref id="scirp.94581-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mackey, T.K. and Nayyar, G. (2017) A Review of Existing and Emerging Digital Technologies to Combat the Global Trade in Fake Medicines. Expert Opinion on Drug Safety, 16, 587-602. https://doi.org/10.1080/14740338.2017.1313227</mixed-citation></ref><ref id="scirp.94581-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Altman, D., Antes, G., et al. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine, 6, e1000097. https://doi.org/10.1371/journal.pmed.1000097</mixed-citation></ref><ref id="scirp.94581-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Amin, A.S., El-Fetouh Gouda, A.A., El-Sheikh, R. and Zahran, F. (2007) Spectrophotometric Determination of Gatifloxacin in Pure Form and in Pharmaceutical Formulation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 67, 1306-1312. https://doi.org/10.1016/j.saa.2006.09.041</mixed-citation></ref><ref id="scirp.94581-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ashour, S. and Bayram, R. (2015) Development and Validation of Sensitive Kinetic Spectrophotometric Method for the Determination of Moxifloxacin Antibacterial Agent in Pure and Commercial Tablets. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 140, 216-222. https://doi.org/10.1016/j.saa.2014.12.111</mixed-citation></ref><ref id="scirp.94581-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Gouda, A.A., Hashem, H. and Hassan, W. (2012) Spectophotometric Methods for Determination of Cefdinir in Pharmaceutical Formulations via Derivatization with 1,2-Naphthoquinone-4-Sulfonate and 4-Chloro-7-Nitrobenzo-2-Oxa-1, 3-Diazole. Drug Testing and Analysis, 4, 991-1000. https://doi.org/10.1002/dta.280</mixed-citation></ref><ref id="scirp.94581-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Babu, K.R., Kumari, N.A. and Vasundhara, A. (2014) A Noval Method Development and Validation of Imipenem in Bulk and Injection Formulations by Spectrophotometric and Rp-Hplc Methods. World Journal of Pharmacy and Pharmaceutical Sciences, 3, 986-1002.</mixed-citation></ref><ref id="scirp.94581-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Rufino, J.L., Pezza, H.R. and Pezza, L. (2008) Flow-Injection Spectrophotometric Determination of Azithromycin in Pharmaceutical Formulations Using p-Chloranil in the Presence of Hydrogen Peroxide. Analytical Sciences, 24, 871-876. https://doi.org/10.2116/analsci.24.871</mixed-citation></ref><ref id="scirp.94581-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Salem, H. (2004) Selective Spectrophotometric Determination of Phenolic β-Lactam Antibacterial Agents in Pure Forms and in Their Pharmaceutical Formulations. Analytica Chimica Acta, 515, 333-341. https://doi.org/10.1016/j.aca.2004.03.056</mixed-citation></ref><ref id="scirp.94581-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Salem, H. and Saleh, G. (2002) Selective Spectrophotometric Determination of Phenolic Beta-Lactam Antibacterial Agents. Journal of Pharmaceutical and Biomedical Analysis, 28, 1205-1213. https://doi.org/10.1016/S0731-7085(02)00027-4</mixed-citation></ref><ref id="scirp.94581-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Hassan, S.S., Hayat, U., Tariq, I., Ahmad, I., Hayat, M.M., Uzair, M., et al. (2014) Spectrophotometric Method for the Determination of Gemifloxacin Mesylate in Pure and Tablet Dosage Form. Pakistan Journal of Pharmaceutical Sciences, 27, 1171-1174.</mixed-citation></ref><ref id="scirp.94581-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Souza, M.J., Canedo, N.A.P., Souza Filho, P.S. and Bergold, A.M. (2009) Development of an Ultraviolet Spectrophotometric Method for the Determination of Ceftiofur Sodium Powder. Journal of AOAC International, 92, 1673-1680.</mixed-citation></ref><ref id="scirp.94581-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Mendez, A.S.L., Steppe, M. and Schapoval, E.E.S. (2003) Validation of HPLC and UV Spectrophotometric Methods for the Determination of Meropenem in Pharmaceutical Dosage Form. Journal of Pharmaceutical and Biomedical Analysis, 33, 947-954. https://doi.org/10.1016/S0731-7085(03)00366-2</mixed-citation></ref><ref id="scirp.94581-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Motwani, S.K., Chopra, S., Ahmad, F.J. and Khar, R.K. (2007) Validated Spectrophotometric Methods for the Estimation of Moxifloxacin in Bulk and Pharmaceutical Formulations. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 68, 250-256. https://doi.org/10.1016/j.saa.2006.11.023</mixed-citation></ref><ref id="scirp.94581-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, M., Babu, S. and Shetty, S. (2011) Development and Validation of Amoxicillin by RP-HPLC Method in Bulk Drug and Pharmaceutical Dosage Forms. International Journal of ChemTech Research, 3, 1037-1041.</mixed-citation></ref><ref id="scirp.94581-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Bellur Atici, E., Yazar, Y., Agtas, &amp;Ccedil;., Ridvanoglu, N. and Karliga, B. (2017) Development and Validation of Stability Indicating HPLC Methods for Related Substances and Assay Analyses of Amoxicillin and Potassium Clavulanate Mixtures. Journal of Pharmaceutical and Biomedical Analysis, 136, 1-9. https://doi.org/10.1016/j.jpba.2016.12.032</mixed-citation></ref><ref id="scirp.94581-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Tavakoli, N., Varshosaz, J., Dorkoosh, F. and Zargarzadeh, M.R. (2007) Development and Validation of a Simple HPLC Method for Simultaneous in Vitro Determination of Amoxicillin and Metronidazole at Single Wavelength. Journal of Pharmaceutical and Biomedical Analysis, 43, 325-329. https://doi.org/10.1016/j.jpba.2006.06.002</mixed-citation></ref><ref id="scirp.94581-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Darwish, K.M., Salama, I., Mostafa, S. and El-Sadek, M. (2013) RP-HPLC/Pre-Column Derivatization for Analysis of Omeprazole, Tinidazole, Doxycycline and Clarithromycin. Journal of Chromatographic Science, 51, 566-576. https://doi.org/10.1093/chromsci/bms167</mixed-citation></ref><ref id="scirp.94581-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Dhal, C., Ahmad, F.J., Chauhan, A., Jyothi, M., Singh, R.M., Saini, P.K., et al. (2015) Quality by Design Approach for Simultaneous Estimation of Doxycycline Hyclate and Curcumin by RP-HPLC Method. Indian Journal of Pharmaceutical Sciences, 77, 723-728.</mixed-citation></ref><ref id="scirp.94581-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Elkhoudary, M., Salam, R. and Hadad, G. (2014) Robustness Testing in HPLC Analysis of Clarithromycin, Norfloxacin, Doxycycline, Tinidazole and Omeprazole in Pharmaceutical Dosage forms Using Experimental Design. Current Pharmaceutical Analysis, 10, 58-70. https://doi.org/10.2174/157341291001140102111733</mixed-citation></ref><ref id="scirp.94581-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Kogawa, A.C. and Salgado, H.R.N. (2013) Quantification of Doxycycline Hyclate in Tablets by HPLC-UV Method. Journal of Chromatographic Science, 51, 919-925. https://doi.org/10.1093/chromsci/bms190</mixed-citation></ref><ref id="scirp.94581-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Djurdjevic, P., Ciric, A., Djurdjevic, A. and Stankov, M.J. (2009) Optimization of Separation and Determination of Moxifloxacin and Its Related Substances by RP-HPLC. Journal of Pharmaceutical and Biomedical Analysis, 50, 117-126. https://doi.org/10.1016/j.jpba.2009.03.029</mixed-citation></ref><ref id="scirp.94581-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Razzaq, S.N., Khan, I.U., Mariam, I. and Razzaq, S.S. (2012) Stability Indicating HPLC Method for the Simultaneous Determination of Moxifloxacin and Prednisolone in Pharmaceutical Formulations. Chemistry Central Journal, 6, 438. https://doi.org/10.1186/1752-153X-6-94</mixed-citation></ref><ref id="scirp.94581-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Elkady, E.F. and Abbas, S.S. (2011) Development and Validation of a Reversed-Phase Column Liquid Chromatographic Method for the Determination of Five Cephalosporins in Pharmaceutical Preparations. Journal of AOAC International, 94, 1440-1446. https://doi.org/10.5740/jaoacint.10-368</mixed-citation></ref><ref id="scirp.94581-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Daidone, F., Heuvelmans, R., Aerden, L., Hoogmartens, J. and Adams, E. (2008) Development of a Liquid Chromatography Method for the Analysis of Josamycin. Journal of Pharmaceutical and Biomedical Analysis, 48, 347-355. https://doi.org/10.1016/j.jpba.2008.02.002</mixed-citation></ref><ref id="scirp.94581-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Acharya, D.R. and Patel, D.B. (2013) Development and Validation of RP-HPLC Method for Simultaneous Estimation of Cefpodoxime Proxetil and Dicloxacillin Sodium in Tablets. Indian Journal of Pharmaceutical Sciences, 75, 31-35. https://doi.org/10.4103/0250-474X.113538</mixed-citation></ref><ref id="scirp.94581-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Gaudin, K., Kauss, T., Gaubert, A., Viaud, V., Dubost, J.P., Olliaro, P., et al. (2011) Simultaneous Determination of Artemether and Azithromycin in Suppositories by Reversed Phase HPLC. Analytical Letters, 44, 2732-2743. https://doi.org/10.1080/00032719.2011.553014</mixed-citation></ref><ref id="scirp.94581-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Shaikh, K.A., Patil, S.D. and Devkhile, A.B. (2008) Development and Validation of a Reversed-Phase HPLC Method for Simultaneous Estimation of Ambroxol Hydrochloride and Azithromycin in Tablet Dosage Form. Journal of Pharmaceutical and Biomedical Analysis, 48, 1481-1484. https://doi.org/10.1016/j.jpba.2008.09.031</mixed-citation></ref><ref id="scirp.94581-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Kahsay, G., Maxa, J., Van Schepdael, A., Hoogmartens, J. and Adams, E. (2012) Development and Validation of a Reversed-Phase Liquid Chromatographic Method for Analysis of Demeclocycline and Related Impurities. Journal of Separation Science, 35, 1310-1318. https://doi.org/10.1002/jssc.201101071</mixed-citation></ref><ref id="scirp.94581-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Kahsay, G., Shraim, F., Villatte, P., Rotger, J., Cassus-Couss&amp;egrave;re, C., Van Schepdael, A., et al. (2013) Development and Validation of a Reversed Phase Liquid Chromatographic Method for Analysis of Oxytetracycline and Related Impurities. Journal of Pharmaceutical and Biomedical Analysis, 75, 199-206. https://doi.org/10.1016/j.jpba.2012.11.042</mixed-citation></ref><ref id="scirp.94581-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Malathi, S., Dubey, R. and Venkatnarayanan, R. (2009) Simultaneous RP-HPLC Estimation of Cefpodoxime Proxetil and Clavulanic Acid in Tablets. Indian Journal of Pharmaceutical Sciences, 71, 102-105. https://doi.org/10.4103/0250-474X.51945</mixed-citation></ref><ref id="scirp.94581-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Sahoo, D.R. and Jain, S. (2016) A Rapid and Validated RP-HPLC Method for the Simultaneous Quantification of Benzoic Acid, Metronidazole and Miconazole Nitrate in Vaginal Formulations. Journal of Chromatographic Science, 54, 1613-1618. https://doi.org/10.1093/chromsci/bmw113</mixed-citation></ref><ref id="scirp.94581-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Smyrniotakis, C.G. and Archontaki, H.A. (2007) C18 Columns for the Simultaneous Determination of Oxytetracycline and Its Related Substances by Reversed-Phase High Performance Liquid Chromatography and UV Detection. Journal of Pharmaceutical and Biomedical Analysis, 43, 506-514. https://doi.org/10.1016/j.jpba.2006.07.048</mixed-citation></ref><ref id="scirp.94581-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Venugopal, K., Snehalatha, M., Bende, G. and Saha, R. (2007) Development and Validation of an Ion-Pairing RP-HPLC Method for the Estimation of Gatifloxacin in Bulk and Formulations. Journal of Chromatographic Science, 45, 220-225. https://doi.org/10.1093/chromsci/45.4.220</mixed-citation></ref><ref id="scirp.94581-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Zalewski, P., Garbacki, P., Cielecka-Piontek, J., Bednarek-Rajewska, K. and Krause, A. (2015) Development and Validation of the Stability-Indicating LC-UV Method for Determination of Cefozopran Hydrochloride. Acta Poloniae Pharmaceutica-Drug Research, 72, 423-427.</mixed-citation></ref><ref id="scirp.94581-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Zalewski, P., Skibiński, R., Cielecka-Piontek, J. and Bednarek-Rajewska, K. (2014) Development and Validation of Stability-Indicating HPLC Method for Determination of Cefpirome Sulfate. Acta Poloniae Pharmaceutica, 71, 731-736.</mixed-citation></ref><ref id="scirp.94581-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Kotkar, R.P., Shirkhedkar, A.A. and Surana, J. (2012) Development and Validation of RP-HPLC Method for Simultaneous Estimation of Cefpodoxime Proxetil and Ambroxol Hydrochloride in Bulk and in Tablets. International Journal of Research in Pharmaceutical and Biomedical Sciences, 3, 156-159.</mixed-citation></ref><ref id="scirp.94581-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Sanli, S., Sanli, N., Gumustas, M., Ozkan, S.A., Karadas, N. and Aboul-Enein, H.Y. (2011) Simultaneous Estimation of Ceftazidime and Ceftizoxime in Pharmaceutical Formulations by HPLC Method. Chromatographia, 74, 549-558. https://doi.org/10.1007/s10337-011-2116-1</mixed-citation></ref><ref id="scirp.94581-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Platzer, D.J. and White, B.A. (2006) Development and Validation of a Gradient HPLC Method for the Determination of Clindamycin and Related Compounds in a Novel Tablet Formulation. Journal of Pharmaceutical and Biomedical Analysis, 41, 84-88. https://doi.org/10.1016/j.jpba.2005.10.020</mixed-citation></ref><ref id="scirp.94581-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Batrawi, N., Wahdan, S. and Al-Rimawi, F. (2017) A Validated Stability-Indicating HPLC Method for Simultaneous Determination of Amoxicillin and Enrofloxacin Combination in an Injectable Suspension. Scientia Pharmaceutica, 85, 6. https://doi.org/10.3390/scipharm85010006</mixed-citation></ref><ref id="scirp.94581-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Arayne, M.S., Sultana, N. and Siddiqui, F.A. (2007) Optimization of Levofloxacin Analysis by RP-HPLC Using Multivariate Calibration Technique. Pakistan Journal of Pharmaceutical Sciences, 20, 100-106.</mixed-citation></ref><ref id="scirp.94581-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Abualhasan, M.N., Batrawi, N., Sutcliffe, O.B. and Zaid, A.N. (2012) A Validated Stability-Indicating HPLC Method for Routine Analysis of an Injectable Lincomycin and Spectinomycin Formulation. Scientia Pharmaceutica, 80, 977-986. https://doi.org/10.3797/scipharm.1207-13</mixed-citation></ref><ref id="scirp.94581-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, S.A., Debnath, M., Rao, J.V.L.N.S., Chaitanya, B., Durga, A., Ramya, G.P.S., et al. (2014) Rapid and Sensitive Rp-Hplc Analytical Method Development &amp; Validation for Estimation of Rifampicin in Bulk as Well as in Pharmaceutical Formulation by Using PDA Detector. Indo American Journal of Pharmaceutical Research, 4, 1561-1572.</mixed-citation></ref><ref id="scirp.94581-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Aucamp, M.E., Csongradi, C., Gerber, M. and Du Plessis, J. (2016) A Novel RP-HPLC Method for the Detection and Quantification of Roxithromycin in Topical Delivery Studies. Pharmazie, 71, 175-176.</mixed-citation></ref><ref id="scirp.94581-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.Y., Wang, Y., Walsh, T.R., Yi, L.X., Zhang, R., Spencer, J., et al. (2016) Emergence of Plasmid-Mediated Colistin Resistance Mechanism MCR-1 in Animals and Human Beings in China: A Microbiological and Molecular Biological Study. The Lancet Infectious Diseases, 16, 161-168. https://doi.org/10.1016/S1473-3099(15)00424-7</mixed-citation></ref><ref id="scirp.94581-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Faller, B. and Ertl, P. (2007) Computational Approaches to Determine Drug Solubility. Advanced Drug Delivery Reviews, 59, 533-545. https://doi.org/10.1016/j.addr.2007.05.005</mixed-citation></ref><ref id="scirp.94581-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Simon, M.-O. and Li, C.-J. (2012) Green Chemistry Oriented Organic Synthesis in Water. Chemical Society Reviews, 41, 1415-1427. https://doi.org/10.1039/C1CS15222J</mixed-citation></ref><ref id="scirp.94581-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Jouyban, A. (2008) Review of the Cosolvency Models for Predicting Solubility of Drugs in Water-Cosolvent Mixtures. Journal of Pharmacy &amp; Pharmaceutical Sciences, 11, 32-58. https://doi.org/10.18433/J3PP4K</mixed-citation></ref><ref id="scirp.94581-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Gordillo, M.D., Blanco, M.A., Molero, A. and Martinez De La Ossa, E. (1999) Solubility of the Antibacterial Agent Penicillin G in Supercritical Carbon Dioxide. The Journal of Supercritical Fluids, 15, 183-190. https://doi.org/10.1016/S0896-8446(99)00008-X</mixed-citation></ref><ref id="scirp.94581-ref69"><label>69</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Turel</surname><given-names> I. </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>The Interactions of Metal Ions with Quinolone Antibacterial Agents</article-title><source> Coordination Chemistry Reviews</source><volume> 232</volume>,<fpage> 27</fpage>-<lpage>47</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.94581-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Welch, C.J., Brkovic, T., Schafer, W. and Gong, X. (2009) Performance to Burn? Re-Evaluating the Choice of Acetonitrile as the Platform Solvent for Analytical HPLC. Green Chemistry, 11, 1232-1238. https://doi.org/10.1039/b906215g</mixed-citation></ref></ref-list></back></article>